Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Pet humanization trends accelerate alongside successful pipeline launches, driving revenue CAGR above 5% and sparking multiple expansion.
Margin Contraction: Operating margins sustainably drop below 35% due to generic competition and loss of pricing power.
Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow.
Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow.
Intangible assets via unmatched patent portfolio and brand loyalty.
High switching costs for veterinary practitioners integrated into the Zoetis ecosystem.
Accelerating pet humanization driving inelastic, premium companion animal healthcare spending.
Strong Buy. Extreme market dislocation implies structural decay, vastly underestimating the 22.7% ROIC and companion animal inelasticity.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
A macroeconomic shock compressing discretionary pet spending combined with a cyclical livestock downturn would threaten historical 37% operating margins. The reverse DCF implies the market is already pricing in a structural decay (-2.52% perpetual growth), providing a massive margin of safety against such cyclical shocks.
Intangible assets via unmatched patent portfolio and brand loyalty.
High switching costs for veterinary practitioners integrated into the Zoetis ecosystem.
Scale economies driving industry-leading 71.8% gross margins.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $2.7B after capex $615.4M, with terminal value at 66.8% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If operating margins hold above 37%, the compounder thesis remains perfectly intact. If companion volume drops significantly, reassess the terminal growth multiple.
If operating margins hold above 37%, the compounder thesis remains perfectly intact. If companion volume drops significantly, reassess the terminal growth multiple.
If operating margins hold above 37%, the compounder thesis remains perfectly intact. If companion volume drops significantly, reassess the multiple.
Asset-light model (capex ~6% of revenue) enables massive capital return ($3.2B buybacks in 2025) across all macro phases.
Accelerating pet humanization driving inelastic, premium companion animal healthcare spending.
Constrained consumer discretionary income and cyclical livestock pricing pressures.
Asset-light model (capex ~6% of revenue) enables massive capital return ($3.2B buybacks in 2025) across all macro phases.
Reevaluate thesis immediately if operating margins break below 35% or if structural ROIC drops precipitously toward the cost of capital.
Strong Buy. Zoetis represents an extreme value dislocation for a premier mature compounder. The $139.77 composite fair value provides massive upside against irrational market pessimism.
The market is heavily discounting ZTS due to unwarranted inclusion in human-pharma peer baskets, completely ignoring its wide animal-health moat and 22.7% ROIC.
Strong Buy. Zoetis represents an extreme value dislocation for a premier mature compounder. The $139.77 composite fair value provides massive upside against irrational market pessimism.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Macro pressures constrain pet spend and generic competition erodes pricing power, validating lower market multiples.
Operating margins sustainably drop below 35% due to generic competition and loss of pricing power.
Prolonged livestock disease cycle reduces the agricultural segment revenues structurally, dragging corporate growth.
Deep recession forces broad reduction in discretionary companion animal treatments and veterinary visits.
The five developments that would weaken our investment case.
Severe operating margin compression reflects an erosion of pricing power across core veterinary franchises or rapid escalation in commercial overhead. Losing high-margin operational leverage impairs cash conversion and undermines the company's valuation premium over standard specialty pharmaceutical manufacturers.
Current:38.0% for the period ended 2025-12-31
Alert ifOperating margin contracts below 35.0% over two consecutive quarters
Sustained contraction in net profitability signals stalling commercial demand and diminishing pricing leverage in companion animal care. Negative bottom-line trajectory invalidates expectations for compounding growth, reducing capital available for internal pipeline reinvestment and triggering severe multiple de-rating.
Current:$6.02 for the period ended 2025-12-31
Alert ifDiluted EPS year-over-year growth falls below 0.0% over two consecutive quarters
A sharp contraction in capital returns signals eroding economic moats and decaying returns on manufacturing and research investments. When returns converge toward the corporate cost of capital, economic value creation evaporates, destroying the core compounding rationale for holding the stock.
Current:22.5% as of 2026-05-12
Alert ifROIC declines below 12.0% over a four-quarter period
Falling gross margins indicate intense channel discounting, rising active pharmaceutical ingredient costs, or an unfavorable shift toward lower-margin livestock products. Breaching the established profitability floor directly reduces cash flow generation, preventing operating leverage from offsetting broader clinical research and distribution expenditures.
Current:71.8% for the period ended 2025-12-31
Alert ifGross margin declines below 70.0% over two consecutive quarters
Rapid introduction of low-cost generic copies undermines brand exclusivity and forces defensive price discounting across high-margin flagship lines. Loss of market exclusivity accelerates volume loss among veterinary clinics, permanently impairing revenue growth and compressing long-term operating cash flows.
Current:Proprietary patent exclusivity across parasiticide and dermatology portfolios as of 2026-05-12
Alert if1 or more regulatory approvals of competing generic alternatives in core parasiticide or dermatology portfolios within a 12-month period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Pet humanization trends accelerate alongside successful pipeline launches, driving revenue CAGR above 5% and sparking multiple expansion.
Steady mid-single digit growth with stable 37% operating margins, capturing the 22.7% ROIC duration effectively via moat fade models.
If operating margins hold above 37%, the compounder thesis remains perfectly intact. If companion volume drops significantly, reassess the terminal growth multiple.
Warning level: Operating margin contracts below 35.0% over two consecutive quarters. Severe operating margin compression reflects an erosion of pricing power across core veterinary franchises or rapid escalation in commercial overhead. Losing high-margin operational leverage impairs cash conversion and undermines the company's valuation premium over standard specialty pharmaceutical manufacturers.
Warning level: Diluted EPS year-over-year growth falls below 0.0% over two consecutive quarters. Sustained contraction in net profitability signals stalling commercial demand and diminishing pricing leverage in companion animal care. Negative bottom-line trajectory invalidates expectations for compounding growth, reducing capital available for internal pipeline reinvestment and triggering severe multiple de-rating.
Warning level: ROIC declines below 12.0% over a four-quarter period. A sharp contraction in capital returns signals eroding economic moats and decaying returns on manufacturing and research investments. When returns converge toward the corporate cost of capital, economic value creation evaporates, destroying the core compounding rationale for holding the stock.
Warning level: Gross margin declines below 70.0% over two consecutive quarters. Falling gross margins indicate intense channel discounting, rising active pharmaceutical ingredient costs, or an unfavorable shift toward lower-margin livestock products. Breaching the established profitability floor directly reduces cash flow generation, preventing operating leverage from offsetting broader clinical research and distribution expenditures.
Warning level: 1 or more regulatory approvals of competing generic alternatives in core parasiticide or dermatology portfolios within a 12-month period. Rapid introduction of low-cost generic copies undermines brand exclusivity and forces defensive price discounting across high-margin flagship lines. Loss of market exclusivity accelerates volume loss among veterinary clinics, permanently impairing revenue growth and compressing long-term operating cash flows.
| $8.54B |
| $9.26B |
| $9.47B |
| +5.4% |
| Gross profit | $5.63B | $5.98B | $6.54B | $6.80B | +6.5% |
| Operating income | $2.88B | $3.18B | $3.36B | $3.58B | +7.6% |
| Net income | $2.11B | $2.34B | $2.49B | $2.67B | +8.1% |
| EPS (diluted) | $4.49 | $5.07 | $5.47 | $6.02 | +10.3% |
| EBITDA | $3.34B | $3.67B | $3.86B | $4.07B | +6.8% |
| R&D | $539.0M | $614.0M | $686.0M | $698.0M | +9.0% |
| SG&A | $2.01B | $2.15B | $2.32B | $2.38B | +5.8% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 9,467,000,000 |
|---|---|
| Cost of revenue | 2,666,000,000 |
| Gross profit | 6,801,000,000 |
| Operating expenses | 3,204,000,000 |
| Operating income | 3,597,000,000 |
| Non-operating items and tax | -924,000,000 |
| Net income | 2,673,000,000 |
| Total assets | 15,467,000,000 |
|---|---|
| Cash | 2,310,000,000 |
| Current assets | 6,768,000,000 |
| Total liabilities | 12,136,000,000 |
| Current liabilities | 2,235,000,000 |
| Shareholders’ equity | 3,331,000,000 |
Point-in-time financial data used in the 2026-05-12 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | 8.1B | 3.3B | 2.1B | 1.9B | 1.3B | 586M | 465M | 62M | 1.6B | 611M | 1.4B | — | — | — | — | 3.6B | 8.1B | 36.2% | — | 7.4% | — |
| 2023-12-31 | 8.5B | 3.7B | 2.3B | 2.4B | 1.6B | 732M | 491M | 60M | 1.1B | 692M | -1.3B | — | — | — | — | 2B | 6.8B | 35.9% | — | 7.7% | — |
| 2024-12-31 | 9.3B | 3.9B | 2.5B | 3B | 2.3B | 655M | 497M | 74M | 1.9B | 786M | -3M | — | — | — | — | 2B | 6.7B | 36.6% | — | 8.2% | — |
| 2025-12-31 | 9.5B | 4.1B | 2.7B | 2.9B | 2.3B | 621M | 487M | 83M | 3.2B | 889M | 2.5B | — | — | — | — | 2.3B | 9.2B | 38.0% | — | 7.6% | — |
ZTS trades at 10.3x forward earnings against a peer median of 17.4x; EV/EBITDA of 9.7x against a peer median of 16.5x; 6 peers.
| Immediate entry. The market is demonstrably mispricing terminal growth at an implied -2.52%. |
| Eli Lilly and Company |
| 21.8x |
| 11.9x |
| 24.9x |
| 107.5% |
| 49.4% |
| JNJ | Johnson & Johnson | 17.4x | 5.5x | 16.5x | 26.4% | 27.4% |
| ABBV | AbbVie Inc. | 12.5x | 5.7x | 14.0x | 62.2% | 32.2% |
| UNH | UnitedHealth Group Incorporated | 18.5x | 0.8x | 18.8x | 12.2% | 8.0% |
